EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis

Adrian Gervais, Paul Bastard iD, Qian Zhang iD, Marie-Christine Jaffar-Bandjee, Lucy Bizien, Lotfi Dahmane, Marie-Pierre Moiton, Julien Jabot, Radj Cally, Alexis Maillard, Etienne Frumence, Xavier de Lamballerie und 10 weitere

Proceedings of the National Academy of Sciences · 27.01.2026 · 123 (4)

DOI: 10.1073/pnas.2532212123 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 22.01.2026. Verfasst von Adrian Gervais und 21 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris 75015, France. Hauptthemen laut MEDLINE: Autoantibodies, Interferon Type I, Chikungunya Fever, Chikungunya virus. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Stavros Niarchos Foundation (SNF), HHS | NIH | National Center for Advancing Translational Sciences (NCATS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human autoantibodies neutralizing type I interferons (IFNs) have emerged as strong, common, and global determinants of a growing number of severe viral diseases, including hypoxemic viral pneumonia, arboviral encephalitis, and adverse reaction to the live-attenuated yellow fever virus (YFV) vaccine. Chikungunya virus (CHIKV) is a growing global health concern that the live-attenuated vaccine VLA1553 (IXCHIQ®) was developed to address. In 2025, five unrelated adults (aged 82 to 88) on the island of La Réunion (France) developed severe reactions postvaccination; two died. The three patients with encephalitis (aged 84 to 85), including one lethal case, had immunoglobulin G autoantibodies in the blood neutralizing high concentrations of both IFN-α and -ω on admission. An 82-y-old survived rhabdomyolysis without encephalitis, and an 88-y-old died during hospitalization following CHIKV infection despite late vaccination; both lacked autoantibodies against type I IFNs. Autoantibodies neutralizing type I IFNs underlie all three cases of live-attenuated CHIKV vaccine encephalitis studied. Individuals with autoantibodies neutralizing type I IFNs should not be inoculated with live-attenuated YFV and CHIKV vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesInterferon Type IChikungunya FeverChikungunya virusViral VaccinesEncephalitis, ViralHumansAged, 80 and overMaleVaccines, AttenuatedFemaleAntibodies, NeutralizingAntibodies, Viral

Stichwörter der Autor:innen

chikungunya vaccine encephalitishuman autoantibodieslive-attenuated vaccinestype I interferons

Substanzen

AutoantibodiesVaccines, AttenuatedInterferon Type IAntibodies, NeutralizingViral VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris 75015, France.
  • Imagine Institute, Paris Cité University, Paris 75015, France.
  • St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.
  • Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris 75015, France.
  • Associated National Reference Center for Arboviruses, Centre Hospitalier Universitaire-Réunion, Saint-Denis, La Réunion 97400, France.
  • Laboratoire de Microbiologie, Centre Hospitalier Universitaire de la Réunion-Site Nord, Saint-Denis, La Réunion 97400, France.

ORCID-Profile: Paul Bastard, Qian Zhang, Aurélie Cobat, Anne Puel, Jean-Laurent Casanova

Förderung

  • Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS)
  • Stavros Niarchos Foundation (SNF)
  • HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
  • Fondation pour la Recherche Médicale (FRM)
  • EC | HORIZON EUROPE Framework Programme (Horizon Europe)
  • NIAID NIH HHS
  • Agence Nationale de la Recherche (ANR)
  • NCATS NIH HHS

Zitieren

APA

Gervais, A., Bastard, P., Zhang, Q., Jaffar-Bandjee, M. C., Bizien, L., Dahmane, L., Moiton, M. P., Jabot, J., Cally, R., Maillard, A., Frumence, E., de Lamballerie, X., Yazdanpanah, Y., Rosain, J., Cobat, A., Abel, L., Puel, A., Ferdynus, C., Mosnier, É., …, & Casanova, J. L. (2026). Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis. Proceedings of the National Academy of Sciences, 123(4). https://doi.org/10.1073/pnas.2532212123

Vancouver

Gervais A, Bastard P, Zhang Q, Jaffar-Bandjee MC, Bizien L, Dahmane L, et al. Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis. Proceedings of the National Academy of Sciences. 2026;123(4). doi:10.1073/pnas.2532212123

BibTeX
@article{Gervais2026,
  author = {Gervais, Adrian and Bastard, Paul and Zhang, Qian and Jaffar-Bandjee, Marie-Christine and Bizien, Lucy and Dahmane, Lotfi and Moiton, Marie-Pierre and Jabot, Julien and Cally, Radj and Maillard, Alexis and Frumence, Etienne and de Lamballerie, Xavier and Yazdanpanah, Yazdan and Rosain, Jérémie and Cobat, Aurélie and Abel, Laurent and Puel, Anne and Ferdynus, Cyril and Mosnier, Émilie and Gérardin, Patrick and Zhang, Shen-Ying and Casanova, Jean-Laurent},
  title = {Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {4},
  doi = {10.1073/pnas.2532212123}
}
Kostenlos starten →